Genetic test may Fine-Tune breast cancer therapy choices
NCT ID NCT03961880
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This study involved 270 women with early-stage, hormone-receptor-positive breast cancer. Researchers wanted to see how a genetic test called OncotypeDX, which gives a recurrence score, influences doctors' treatment recommendations. They also checked if the score was linked to cancer cells found in the bone marrow. The goal was to better understand how to personalize treatment and avoid unnecessary chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department for Women's Health
Tübingen, Baden-Wurttemberg, 72086, Germany
Conditions
Explore the condition pages connected to this study.